Biology of cachexia

Journal of the National Cancer Institute

Volumn 89, Issue 23, 1997, Pages 1763-1773

  Tisdale, Michael J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; FATTY ACID; GAMMA INTERFERON; GLUCOSE; HYDRAZINE SULFATE; IBUPROFEN; ICOSAPENTAENOIC ACID; INTERLEUKIN 1; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANOREXIA; APPETITE; CACHEXIA; CLINICAL TRIAL; ENERGY EXPENDITURE; GLUCONEOGENESIS; HUMAN; NONHUMAN; PANCREAS CANCER; REVIEW; SKELETAL MUSCLE; SURVIVAL TIME; TOTAL PARENTERAL NUTRITION; WEIGHT REDUCTION;

EID: 0030665384     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.23.1763     Document Type: Review

References (138)

1. Moley JF, Aamodt R, Rumble W, Kaye W, Norton JA. Body cell mass in cancer bearing and anorexia patients. J Parenter Enterai Nutr 1987;11: 219-22.
2. DeWys WD. Anorexia as a general effect of cancer. Cancer 1972;45: 2013-19.
3. Costa G. Lane WW,Vincint RG,Siebold JA,Aragon M, Bewley PT. Weight loss and cachexia in lung cancer. Nutr Cancer 1980;2:98-104.
4. Costa G. Cachexia, the metabolic component of neoplastic diseases. Cancer Res 1977;37:2327-35.
5. Ovesen L, Allingstrup L,Hannibal J,Mortensen JL,Hansen OP. Effect of dietary counseling on food intake, body weight, response rate, survival and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 1993;11:2043-9.
6. Heber D,Byerley LO,Chi J,Grosvenor M,Bergman RN,Coleman M. et al. Pathophysiology of malnutrition in the adult cancer patient. Cancer 1986:58(8 Suppl):1867-73.
7. Evans WK,Makuch R,Clamon GH, Feld K, Weiner RS,Moran E. et al. Limited impact of total parenteral nutrition of nutritional status during treatment for small cell lung cancer. Cancer Res 1985;45:3347-53.
8. Padilla GV. Psychological aspects of nutrition and cancer. Surg Clin North Am 1986;66:1121-35.
9. Knoll J. Endogenous anorectic agents - satietins. Annu Rev Pharmacol Toxicol 1988;28:247-68.
10. Chance WT, Balasubramaniam A, Thompson H, Mohapatra B, Ramo J, Fischer JE. Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y. Peptides 1996;17: 797-801.
11. Cangiano C, Testa U, Muscaritoli M, Meguid MM, Mulieri M, Laviano A, et al. Cytokines, tryptophan and anorexia in cancer patients before and after surgical tumor ablation. Anticancer Res 1994;14:1451-5.
12. Cangiano C, Laviano A, Meguid MM, Mulieri M, Conversano L. Preziosa I, et al. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J Natl Cancer Inst 1996; 88:550-2.
13. Kardinal CG, Loprinzi CL, Schaid DJ, Hass AC, Dose AM, Athmann LM, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657-62.
14. Brennan MF. Uncomplicated starvation versus cancer cachexia. Cancer Res 1977;37:2359-64.
15. Knox LS, Crosby LO, Feurer ID, Buzby GP, Miller CL, Mullen JL. Energy expenditure in malnourished cancer patients. Ann Surg 1983;197: 152-62.
16. Nixon DW, Kutner M, Heymsfield S, Foltz AT, Carty C, Seitz S, et al. Resting energy expenditure in lung and colon cancer. Metabolism 1988; 37:1059-64.
17. Lindmark L, Bennegard K, Eden E, Ekman L, Schersten T, Svaninger G, et al. Resting energy expenditure in malnourished patients with and without cancer. Gastroenterology 1984;87:402-8.
18. Hyltander A, Drott C, Korner U, Sandstrom R, Lundholm K. Elevated energy expenditure in cancer patients with solid tumours. Eur J Cancer 1991;27:9-15.
19. Drott C, Svaninger G, Lundholm K. Increased urinary excretion of cortisol and catecholamines in malnourished cancer patients. Ann Surg 1988; 208:645-50.
20. Fredix EW, Soeters PB, Wouters EF, Deerenberg IM, von Meyerfeldt MF, Saris WH. Effect of different tumor types on resting energy expenditure. Cancer Res 1991;51:6138-41.
21. Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994;219:325-31.
22. Brooks SL, Neville AM, Rothwell NJ, Stock MJ, Wilson S. Sympathetic activation of brown-adipose-tissue thermogenesis in cachexia. Biosci Rep 1981;1:509-17.
23. Edstrom S, Kindblom LG, Lindmark L, Lundholm K. Metabolic and morphologic changes in brown adipose tissue from non-growing mice with an isogenic sarcoma. Evaluation with respect to development of cachexia. Int J Cancer 1986;37:753-60.
24. Shellock FG, Riedinger MS, Fishbein MC. Brown adipose tissue in cancer patients: possible cause of cancer-induced cachexia. J Cancer Res Clin Oncol 1986;111:82-5.
25. Nolop KB, Rhodes CG, Brudin LH, Beaney RP, Kravsz T, Jones T, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60:2682-9.
26. Holm E, Hagmuller E, Staedt U, Schlickeiser G, Gunther HJ, Leweling H, et al. Substrate balances across colonic carcinomas in humans. Cancer Res 1995;55:1373-8.
27. Mathupala SP, Rempel A, Pedersen PL. Glucose metabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 1995;270:16918-25.
28. Mulligan HD,Tisdale MJ. Metabolic substrate utilization by tumour and host tissues in cancer cachexia. Biochem J 1991;277:321-6.
29. Tayek JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 1992;11:445-56.
30. Holroyde CP, Reichard GA. Carbohydrate metabolism in cancer cachexia. Cancer Treat Rep 1981;65 Suppl 5:55-9.
31. Shapot VS, Blinov VA. Blood glucose levels and gluconeogenesis in animals bearing transplantable tumors. Cancer Res 1974;34:1827-32.
32. Lundholm K, Holm G, Schersten T. Gluconeogenesis from alanine in patients with progressive malignant disease. Cancer Res 1979;39: 1968-72.
33. Lundholm K, Edstrom S, Karlsberg I, Ekman L, Schersten T. Glucose turnover, gluconeogenesis from glycerol and estimation of net glucose cycling in cancer patients. Cancer 1982;50:1142-50.
34. Holroyde CP, Gabuzda TG, Putnam RC, Paul P, Reichard GA. Altered glucose metabolism in metastatic carcinoma. Cancer Res 1975;35: 3710-4.
35. Eden E, Edstrom S, Bennegard K, Schersten T, Lundholm K. Glucose flux in relation to energy expenditure in malnourished patients with and without cancer during periods of fasting and feeding. Cancer Res 1984; 44:1717-24.
36. Hobbs CB, Miller AL. Review of endocrine syndromes associated with tumours of non-endocrine origin. J Clin Pathol 1966;19:119-27.
37. Zapf J, Futo E, Peter M, Froesch ER. Can 'big' insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J Clin Invest 1992;90:2574-84.
38. Shaw JH, Wolfe RR. Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. Ann Surg 1987;205:368-76.
39. Drott C, Persson H, Lundholm K. Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer. Clin Physiol 1989;9:427-39.
40. Waterhouse C, Kemperman JH. Carbohydrate metabolism in subjects with cancer. Cancer Res 1971;31:1273-8.
41. Costa G, Bewley P, Aragon M, Siebold J. Anorexia and weight loss in cancer patients. Cancer Treat Rep 1981;65:3-7.
42. Edmonson JH. Fatty acid mobilization and glucose metabolism in patients with cancer. Cancer 1966;19:277-80.
43. Yam D, Ben-Hur H, Fink A, Dagani R, Shani A, Eliraz A, et al. Insulin and glucose status, tissue and plasma lipids in patients with tumours of the ovary or endometrium: possible dietary implications. Br J Cancer 1994; 70:1186-7.
44. Wicha MS, Liotta LA, Kidwell WR. Effects of free fatty acids on the growth of normal and neoplastic rat mammary epithelial cells. Cancer Res 1979;39:426-35.
45. Hussey HJ, Tisdale MJ. Effects of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo. Br J Cancer 1994;70:6-10.
46. Tang DG, Chen YO, Honn KV. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci U S A 1996; 93:5241-6.
47. Nixon DW, Heymsfield SB, Cohen AE, Kutner MH, Ansley J, Lawson DH, et al. Protein-caloric undernutrition in hospitalized cancer patients. Am J Med 1980;68:683-90.
48. McMillan DC, Preston T, Watson WS, Simpson JM, Fearon KC, Shenkin A, et al. Relationship between weight loss, reduction of body cell mass and inflammatory response in patients with cancer. Br J Surg 1994;81: 1011-4.
49. Lundholm K, Bylund AC, Holm J, Schersten T. Skeletal muscle metabolism in patients with malignant tumor. Eur J Cancer 1976;12:465-73.
50. Emery PW, Edwards RH, Rennie MJ, Souhami RL, Halliday D. Protein synthesis in muscle measured in vivo in cachectic patients with cancer. Br Med J (Clin Res Ed) 1984;289:584-6.
51. Fearon KC, Hansell DT, Preston T, Plumb JA, Davies J, Shipiro D, et al. Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer. Cancer Res 1988;48:2590-5.
52. Holm E, Hagmuller E, Staedt U, Schlickeiser G, Gunther HJ, Leweling H, et al. Substrate balances across colonie carcinomas in humans. Cancer Res 1995;55:1373-8.
53. Sengelov H, Hansen OP, Simonsen L, Bulow J, Nielson OJ, Ovesen L. Inter-relationships between single carbon units' metabolism and resting energy expenditure in weight-losing patients with small cell lung cancer. Effects of methionine supply and chemotherapy. Eur J Cancer 1994;30A: 1616-20.
54. Wing SS, Goldberg AL. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am J Physiol 1993;264:E668-76.
55. Tiao G, Fagan JM, Samuels N, James JH, Hudson K, Lieberman M, et al. Sepsis stimulates nonlysosomal, energy-dependent proteolysis and increases ubiquitin mRNA levels in rat skeletal muscle. J Clin Invest 1994; 94:2255-64.
56. Mitch WE, Medina R, Grieber S, May RC, England BK, Price SR, et al. Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. J Clin Invest 1994;93:2127-33.
57. Llovera M, Garcia-Martinez C, Agell N, Marzabal M, Lopez-Soriano FJ, Argiles JM. ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Lett 1994;338:311-8.
58. 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest 1995;95:2367-72.
59. Berg M, Fraker DL, Alexander HR. Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-LI adipocytes. Cytokine 1994;6:425-32.
60. Mahony SM, Beck SA, Tisdale MJ. Comparison of weight loss induced by recombinant tumour necrosis factor with that produced by a cachexia-inducing tumour. Br J Cancer 1988;57:385-89.
61. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987;50:555-63.
62. Tracey KJ, Morgello S, Koplin B, Fahey FJ 3d, Fox J, Aledo A, et al. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. J Clin Invest 1990;86:2014-24.
63. Hauner H, Petruschke T, Russ M, Rohrig K, Eckel J. Effects of tumour necrosis factor alpha (TNFα) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologica 1995; 38:764-71.
64. Hall-Angeras M, Angeras U, Zamir O, Hasselgren PO, Fischer JE. Interaction between corticosterone and tumor necrosis factor stimulated protein breakdown in rat skeletal muscle, similar to sepsis. Surgery 1990; 108:460-6.
65. Llovera M, Lopez-Soriano FJ, Argiles JM. Effects of tumor necrosis factor-α on muscle protein turnover in female Wistar rats. J Natl Cancer Inst 1993;85:1334-9.
66. 2 production in rat skeletal muscle in fever is signaled by a macrophage product distinct from interleukin 1 or other known monokines. J Clin Invest 1988;81:1378-83.
67. Llovera M, Garcia-Martinez C, Agell N, Lopez-Soriano FJ, Argiles JM. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun 1997;230: 238-41.
68. Costelli P, Carbo N, Tessitore L, Bagby GJ, Lopez-Soriano FJ, Argiles JM, et al. Tumor necrosis factor-α mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 1993;92:2783-9.
69. Moldawer LL, Svaninger G, Gellin J, Lundholm K. Interleukin-1 and tumour necrosis factor do not regulate protein balance in skeletal muscle. Am J Physiol 1987;253:766-73.
70. Sherry BA, Gelin J, Fong Y, Marano M, Wei H, Cerami A, et al. Anticachectin/tumor necrosis factor-α antibodies attenuate development of cachexia in tumor models. FASEB J 1989;3:1956-62.
71. Starnes HF Jr, Warren RS, Jeevanandam M, Gabrilove JL, Larchian W, Oettgen HF, et al. Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest 1988;82:1321-5.
72. Bartsch HH, Pfizenmaier K, Schroeder M, Nagel GA. Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies. Eur J Cancer Clin Oncol 1989;25:287-91.
73. Socher SH, Martinez D, Craig JB, Kuhn JG, Oliff A. Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst 1988;50:595-8.
74. Thompson MP, Cooper ST, Parry BR, Tuckey JA. Increased expression of the mRNA for the hormone-sensitive lipase in adipose tissue of cancer patients. Biochim Biophys Acta 1993;1180:236-42.
75. Balkwill F, Osborne R, Burke F, Naylor S, Talbot D, Durbin H, et al. Evidence for tumor necrosis factor/cachectin production in cancer. Lancet 1987;2:1229-32.
76. Adami F, Guarini A, Pini M, Siviero F, Sancetta R, Massaia M, et al. Serum levels of tumour necrosis factor-α in patients with B-cell chronic lymphocytic leukaemia. Eur J Cancer 1994;30A:1259-63.
77. Shaarawy M, Abdel-Aziz O. Serum tumour necrosis factor alpha levels in benign and malignant lesions of the endometrium in postmenopausal women. A preliminary study. Acta Oncol 1992;31:417-20.
78. Aderka D, Engelmann H, Hornik V, Skorsick Y, Levo Y, Wallach D, et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 1991;51:5062-7.
79. Scuderi P, Sterling KE, Lam KS, Finley PR, Ryan KJ, Ray CG, et al. Raised serum levels of tumour necrosis factor in parasitic infections. Lancet 1986;2:1364-5.
80. Pearson RD, Cox G, Evans T, Smith DL, Weidel D, Castracane J. Wasting and macrophage production of tumor necrosis factor/cachectin and interleukin 1 in experimental visceral leishmaniasis. Am J Trop Hyg 1990;43: 140-9.
81. Breuille D, Farge MC, Rose F, Arnal M, Attaix D, Obled C. Pentoxifylline decreases body weight loss and muscle protein wasting characteristic of sepsis. Am J Physiol 1993;265:E660-6.
82. Goldberg RM, Loprinzi CL, Malliard JA, O'Fallon JR, Krook JE, Ghosh C, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995;13: 2856-9.
83. Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89:1681-4.
84. Soda K, Kawakami M, Kashii K, Miyata M. Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. Int J Cancer 1995;62:332-6.
85. Strassmann G, Fong M, Freter CE, Windsor S. D'Alessandry F, Nordan RP. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-25 mediated experimental cancer cachexia in vivo. J Clin Invest 1993;92:2152-9.
86. Tamura S, Fujimoto-Ouchi K, Mori K, Endo M, Matsumoto T, Eden H, et al. Involvement of human interleukin 6 in experimental cachexia induced by a human uterine carcinoma xenograft. Clin Cancer Res 1995; 1:1353-8.
87. Mori K, Fujimoto-Ouchi K, Ishikawa T, Sekiguchi F, Ishitsuka H, Tanaka Y. Murine interleukin-12 prevents the development of cancer cachexia in a murine model. Int J Cancer 1996;67:849-55.
88. Matthys P, Dijkmans R, Proost P, Van Damne J, Heremans H, Sobis H, et al. Severe cachexia in mice inoculated with interferon-γ-producing tumor cells. Int J Cancer 1991;49:77-82.
89. Fujiki F, Mukaida N, Hirose K, Ishida H, Harada A, Ohno S, et al. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res 1997;57:94-9.
90. Fujita J, Tsujinaka T, Yano M, Ebisui C, Saito H, Katsume A, et al. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int J Cancer 1996;68:637-43.
91. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 1996; 97:244-9.
92. Goodman MN. Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 1994;205:182-5.
93. 12 myotubes. Clin Sci (Colch) 1995; 89:431-9.
94. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer 1996;73:1560-2.
95. Fearon KC, McMillan DC, Preston T, Winstanley P, Cruickshank AM, Shenkin A. Elevated circulating interleukin-6 is associated with an acute phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg 1991;213:26-31.
96. Moldawer LL, Andersson C, Gelin J, Lundholm KG. Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. Am J Physiol 1988;254:G450-6.
97. Lonnroth C, Moldawer LL, Gelin J, Kindblom L, Sherry B, Lundholm K. Tumor necrosis factor-α and interleukin-1α production in cachectic, tumor-bearing mice. Int J Cancer 1990;46:889-96.
98. Gelin J, Moldawer LL, Lonnroth C, Sherry B, Chizzonite R, Lundholm K. Role of endogenous tumor necrosis factor α and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 1991;51:415-21.
99. Costelli P, Llovera M, Carbo N, Garcia-Martinez C, Lopez-Sorianoq FJ, Argiles JM. Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Lett 1995;95:33-8.
100. Yasumoto K, Mukaida N, Harada A, Kuno K, Akiyama M, Nakashima E, et al. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res 1995;55:921-7.
101. Patton JS, Shepard HM, Wilking H, Lewis G, Aggarwal BB, Eessalu TE, et al. Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proc Natl Acad Sci U S A 1986;83:8313-7.
102. Matthys P, Heremans H, Opdenakker G, Billiau A. Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur J Cancer 1991;27:182-7.
103. Langstein HN, Doherty GM, Fraker DL, Buresh CM, Norton JA. The roles of γ-interferon and tumor necrosis factor α in an experimental rat model of cancer cachexia. Cancer Res 1991;51:2302-6.
104. Matthys P, Dijkmans R, Proost P, Van Damne J, Heremans H, Sobis H, et al. Severe cachexia in mice inoculated with interferon-γ-producing tumor cells. Int J Cancer 1991;49:77-82.
105. Pisa P, Stenke L, Bernell P, Hansson M, Hast R. Tumor necrosis factor-α and interferon-γ in serum of multiple myeloma patients. Anticancer Res 1990;10:817-20.
106. Mori M, Yamaguchi K, Honda S, Nagasaki K, Veda M, Abe O, et al. Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res 1991;51:6656-9.
107. Kajimura N, Iseki H, Tanaka R, Ohue C, Otsubo K, Gyoutoku M, et al. Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines. Cancer Chemother Pharmacol 1996;38 Suppl:S48-52.
108. Tisdale MJ, Beck SA. Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 1991;41:103-7.
109. Costa G, Holland JF. Effect of Krebs-2 carcinoma on the lipide metabolism of male Swiss mice. Cancer Res 1962;22:1081-3.
110. Kralovic RC, Zepp FA, Cenedella RJ. Studies of the mechanism of carcass fat depletion in experimental cancer. Eur J Cancer 1977;13:1071-9.
111. Kitada S, Hays EF, Mead JF. A lipid mobilizing factor in serum of tumor-bearing mice. Lipids 1980;15:168-74.
112. Groundwater P, Beck SA, Barton C, Adamson C, Ferner IN, Tisdale MJ. Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients. Br J Cancer 1990;62:816-21.
113. Beck SA, Groundwater P, Barton C, Tisdale MJ. Alterations in serum lipolytic activity of cancer patients with response to therapy. Br J Cancer 1990;62:822-5.
114. Kitada S, Hays EF, Mead JF. Characterization of a lipid mobilizing factor from tumors. Prog Lipid Res 1981;28:823-6.
115. Taylor DD, Gercel-Taylor C, Jenis LJ, Devereux DF. Identification of a human tumor-derived lipolysis-promoting factor. Cancer Res 1992;52: 829-34.
116. Masuno H, Yamasaki N, Okuda H. Purification and characterization of a lipolytic factor (toxohormone-L) from cell-free fluid of ascites sarcoma 180. Cancer Res 1981;41:284-8.
117. Beck SA, Tisdale MJ. Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res 1987;47: 5919-23.
118. Beck SA, Mulligan HD, Tisdale MJ. Lipolytic factors associated with murine and human cancer cachexia. J Natl Cancer Inst 1990;82: 1922-6.
119. Smith KL, Tisdale MJ. Mechanism of muscle degradation in cancer cachexia. Br J Cancer 1993;68:314-8.
120. Belizario JE, Katz M, Chenker E, Raw I. Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss. Br J Cancer 1991;63:705-10.
121. Todorov PT, McDevitt TM, Cariuk P, Coles B, Deacon M, Tisdale MJ. Induction of muscle protein degradation and weight loss by a tumor product. Cancer Res 1996;56:1256-61.
122. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature 1996;379:739-42.
123. Todorov PT, Deacon M, Tisdale MJ. Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J Biol Chem 1997;272:12279-88.
124. DeWys W. Management of cancer cachexia. Semin Oncol 1985;12: 452-60.
125. Wigmore SJ, Plester CE, Richardson RA, Fearon KC. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 1997;75:106-9.
126. Windsor JA, Hill GL. Risk factors for postoperative pneumonia. The importance of protein depletion. Ann Surg 1988;208:209-14.
127. McGeer AJ, Detsky AS, O'Rourke K. Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis. Nutrition 1990;6: 233-40.
128. Downer S, Joel S, Allbright A, Plant H, Stubbs L, Talbot D, et al. A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 1993;67:1102-5.
129. Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-32.
130. Gebbia V, Testa A, Gebbia N. Prospective randomized trial of two dose levels of megestrol acetate in the management of anorexia cachexia syndrome in patients with metastatic cancer. Br J Cancer 1996;73:1576-80.
131. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11:152-4.
132. Chlebowski RT, Heber D, Richardson B, Block JB. Influence of hydrazine sulfate on abnormal carbohydrate metabolism in cancer patients with weight loss. Cancer Res 1984;44:857-61.
133. Chlebowski RT, Bulcavage L, Grosvenor M, Tsunokai R, Block JB. Heber D, et al. Hydrazine sulfate in cancer patients with weight loss: a placebo-controlled clinical experience. Cancer 1987;59:406-10.
134. Wigmore SJ, Falconer JS, Plester CE, Ross JA, Maingay JP, Carter DC, et al. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 1995;72:185-8.
135. Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, Carter DC, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996;12:S27-30.
136. Beck SA, Smith KL, Tisdale MJ. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 1991; 51:6089-93.
137. Inagaki J, Rodriguez V, Bodey GP. Proceedings: Causes of death in cancer patients. Cancer 1974;33:568-73.
138. Warren S. The immediate causes of death in cancer. Am J Med Sci 1932;184:610-5.